Prosecution Insights
Last updated: May 04, 2026
Application No. 17/534,614

GRIP FOR MOUNTING A CYSTOTOME TO A SYRINGE, AN ASSEMBLY THEREOF, AND A METHOD RELATED THERETO

Final Rejection §102§103§112
Filed
Nov 24, 2021
Priority
Dec 03, 2020 — provisional 63/120,872
Examiner
TRINH, HONG-VAN N
Art Unit
3783
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Beaver-Visitec International (Us) Inc.
OA Round
4 (Final)
62%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
160 granted / 260 resolved
-8.5% vs TC avg
Strong +59% interview lift
Without
With
+59.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
27 currently pending
Career history
287
Total Applications
across all art units

Statute-Specific Performance

§101
0.5%
-39.5% vs TC avg
§103
40.2%
+0.2% vs TC avg
§102
25.4%
-14.6% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 260 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This office action is responsive to the amendment filed on 4/29/2024. As directed by the amendment: claim 1 has been amended; no claims have been cancelled; and no claims have been added. Thus, claims 1-11 are presently pending in this application. Drawings The Drawings filed 4/29/2024 have been accepted. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites “a majority of the length of the body is located between the female luer fitting and the male luer fitting”. It is unclear whether the length is entirely between the female luer fitting and the male luer fitting (as the claim recites the length as being "between first and second ends" which the claim further describes as defining the female luer fitting and male luer fitting respectively) or whether only a majority of the length (which implies less than the entirety of the length) is between the female luer fitting and the male luer fitting as the language in lines 9-10 of claim 1 would indicate. Dependent claims are rejected by virtue of their dependency on the independent claims. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1-6 and 8 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gilson et al. (US 4369781 A). Regarding claim 1, Gilson discloses a grip (10) for mounting to a syringe (84) having a luer tip (86) with a liquid outlet defined at a distal end thereof (Col 4, lines 5-7), the grip comprising: an elongated body (12) extending a length (Image 1) along a longitudinal axis between first and second ends (Image 1), the first end defining a female luer fitting (28) configured for mounting onto the luer tip of the syringe (Fig. 4), an inlet opening (30) being defined in the female luer fitting formed to align with the liquid outlet of the luer tip with the female luer fitting mounted to the luer tip (Fig. 4), the second end defining a male luer fitting (14) defining an outlet opening (20) at a distal end thereof (Fig. 1), and, a liquid passageway (Passagewafy within 12 between 20 and 30) defined through the body between the inlet opening and the outlet opening to allow liquid flow therebetween (Col 4, lines 5-7), wherein, a majority of the length of the body is located between the female luer fitting and the male luer fitting (Image 1), and, wherein, the body defines an outer surface (32) encircling the longitudinal axis (Fig. 1), the outer surface being at least partially textured (Col 4, lines 30-32). Image 1: PNG media_image1.png 334 644 media_image1.png Greyscale Regarding claim 2, Gilson discloses the grip of claim 1, wherein the diameter of the body varies along the longitudinal axis (Fig. 1). Regarding claim 3, Gilson discloses the grip of claim 2, wherein the body defines a concave shape (Spaces between two adjacent longitudinal ribs on the outer surface of wall define a concave shape, Col 4, lines 30-32). Regarding claim 4, Gilson discloses the grip of claim 1, wherein the outer surface is textured by a plurality of spaced-apart discontinuities and/or raised elements (Col 4, lines 30-32). Regarding claim 5, Gilson discloses the grip of claim 4, wherein the outer surface includes a plurality of intersecting ribs (Col 4, lines 30-32, merriam-webster defines “intersecting” as “to pierce or divide by passing through or across” and because the ribs are dividing the body by passing across the body, the ribs are intersecting the body) defining the spaced-apart discontinuities (Col 4, lines 30-32, Fig. 4). Regarding claim 6, Gilson discloses the grip of claim 1, further comprising an internally-threaded collar (24/26) disposed about the male luer fitting (Fig. 1). Regarding claim 8, Gilson discloses the grip of claim 1, wherein the outer surface is textured about a full circumference of the body (Col 4, lines 30-32, Figs. 1 and 4). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim 7 is rejected under 35 U.S.C. 103 as being unpatentable over Gilson et al. (US 4369781 A) in view of Kim et al. (US 20200155770 A1). Regarding claim 7, Gilson discloses the grip of claim 1, but is silent regarding further comprising at least one thread protruding radially outwardly from the female luer fitting. In analogous art, Kim teaches further comprising at least one thread protruding radially outwardly from the female luer fitting (34, Fig. 1, Paragraph [0033], Claim 3). It would have been obvious to one of ordinary skill in the art prior to the effective filing date of the claimed invention to have modified the female luer fitting on Gilson to incorporate the teachings of Kim to incorporate at least one thread protruding radially outwardly from the female luer fitting in order to allow mating with a male luer connector of a syringe barrel (Paragraph [0033]). Claim 9 is rejected under 35 U.S.C. 103 as being unpatentable over Gilson et al. (US 4369781 A) in view of MH Eye Care (“OASIS® Formed Irrigating Cystotome”, 2020). Regarding claim 9, Gilson discloses a syringe assembly (Figs. 1 and 4) for performing a capsulotomy on a patient's eye with a cystotome, the syringe assembly comprising: a syringe (84) having a luer tip (86) with a liquid outlet defined at a distal end thereof (Col 4, lines 5-7); a grip as in claim 1 (See rejection of claim 1 above) with the female luer fitting thereof mounted to the luer tip of the syringe (Fig. 4); and, a cannula (88), distally extending from a hub (90), the hub having a secondary female luer fitting (92) mounted to the male luer fitting of the grip (Fig. 4, Cols 3-4, lines 67-5). Gilson is silent regarding a cystotome, distally extending from a hub, the cystotome configured for incising the lens capsule of the patient's eye, the hub having a secondary female luer fitting mounted to the male luer fitting of the grip. In analogous art, MH Eye Care teaches a cystotome (Image 2), distally extending from a hub (Image 2), the cystotome configured for incising the lens capsule of the patient's eye (Page 2, “OASIS’® Irrigating Cystotome is a crucial instrument in the capsulotomy of the eye to remove cataracts by surgery. With a formed bend, this is a reliable instrument during cataract procedures”, the hub having a secondary female luer fitting (Image 2). Image 2: PNG media_image2.png 629 439 media_image2.png Greyscale The substitution of one known material (irrigating cystotome as taught in MH Eye Care) for another (fluid delivering cannula as taught in Gilson) would have been obvious to one of ordinary skill in the before the effective filing date of the claimed invention since the substitution of the irrigating cystotome as taught in MH Eye Care would have yielded predictable results, namely, a delivering conduit of Gilson that would expel the contents within the syringe. KSR International Co. v. Teleflex Inc., 550 U.S. 398, 82 USPQ2d 1385 (2007). Response to Arguments Applicant's arguments filed 4/29/2024 have been fully considered but they are not persuasive. In response to applicant's arguments, on page 7, that Gilson does not teach “the majority of the length of the body is located between the female luer fitting and the male luer fitting”, the Examiner respectfully disagrees. Claim 1 recites that the elongated body extends "a length along a longitudinal axis between first and second ends" and the current rejection maps this length to the portion/length of the body 12 in Gilson that is between the female luer fitting 28 and the male luer fitting 14, see annotated figure below, thus since this length of the body is entirely between the female luer fitting and the male luer fitting , a majority of this length is also located between the female luer and the male luer. Examiner notes that a 112(b) rejection is given above as the claim is unclear as to whether the length is entirely between the female luer fitting and the male luer fitting (as the claim recites the length as being "between first and second ends" which the claim further describes as defining the female luer fitting and male luer fitting respectively) or whether only a portion/majority of the length is between the female luer fitting and the male luer fitting as the language in lines 9-10 of claim 1 would indicate. PNG media_image1.png 334 644 media_image1.png Greyscale Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to HONG-VAN N TRINH whose telephone number is (571)272-8039. The examiner can normally be reached Monday-Friday 9:15-5:45 ET. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chelsea Stinson can be reached on (571) 270-1744. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /HONG-VAN N TRINH/Examiner, Art Unit 3783 /James D Ponton/Primary Examiner, Art Unit 3783
Read full office action

Prosecution Timeline

Show 2 earlier events
Apr 29, 2024
Response Filed
Jun 03, 2024
Final Rejection — §102, §103, §112
Aug 05, 2024
Response after Non-Final Action
Sep 04, 2024
Request for Continued Examination
Sep 05, 2024
Response after Non-Final Action
Sep 03, 2025
Non-Final Rejection — §102, §103, §112
Dec 05, 2025
Response Filed
Apr 29, 2026
Final Rejection — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12576211
Refill system for medical device using jet delivery principle
3y 5m to grant Granted Mar 17, 2026
Patent 12569589
SYSTEM AND METHODS FOR DELIVERING A DERMAL FILLER
2y 10m to grant Granted Mar 10, 2026
Patent 12558488
SYSTEM AND METHOD FOR MICRODOSE INJECTION
2y 1m to grant Granted Feb 24, 2026
Patent 12551659
CATHETER CONTROL SYSTEMS AND METHODS
2y 10m to grant Granted Feb 17, 2026
Patent 12533463
DISPOSABLE CARTRIDGE FOR A DRUG DELIVERY DEVICE
2y 1m to grant Granted Jan 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
62%
Grant Probability
99%
With Interview (+59.3%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 260 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month